Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U10CA081851 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
RATIONALE: Coenzyme Q10 is a vitamin that may be effective in relieving fatigue and depression in women who are undergoing chemotherapy for breast cancer.
PURPOSE: This randomized clinical trial is studying how well coenzyme Q10 works in relieving treatment-related fatigue in women with breast cancer.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to planned radiotherapy (yes vs no) and type of chemotherapy (anthracycline vs non-anthracycline). Patients are randomized to 1 of 2 treatment arms.
Treatment in both arms continues for 24 weeks in the absence of unacceptable toxicity.
Quality of life, fatigue, and depression are assessed at baseline and at 8, 16, and 24 weeks.
PROJECTED ACCRUAL: A total of 101-236 patients will be accrued for this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 - CoQ10 & Vitamin E | Active Comparator | CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day. |
|
| Arm 2 - Placebo & Vitamin E | Placebo Comparator | Placebo-Vitamin E 100 mg/day in 3 doses |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CoQ10 & Vitamin E | Dietary Supplement |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization | POMS-F is the Profile of Mood States - fatigue scale. It ranges from 0 to 28; higher values indicate greater fatigue. | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Effects of Coenzyme Q10 on Quality of Life (as Measured by FACT-B) 24 Weeks Following Randomization | FACT-B stands for Functional Assessment of Cancer Therapy - Breast. It measures quality of life. It is the total of the FACT subscales (emotional, social, functional, and physical) and the Breast subscale. Scores range from 0 to 144; higher scores reflect better overall quality of life. | 24 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Recent involuntary weight loss (> 5% of body weight in the past 3 months)
Statin therapy - current or planned during study. Below is a list of some commonly used statin drugs.(Note: This is a helpful guide, not a complete list.)
Current or planned use of the following medications for fatigue
Patients diagnosed with uncontrolled hypertension
Breast cancer patients who are male
Pregnant women are excluded from participation in this study. A Serum pregnancy test is required within 1 week of registration if the patient is a woman of childbearing potential.
Anticoagulant therapy - current or planned during study (except for maintenance of catheter patency)
Patients with uncontrolled thyroid dysfunction
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Glenn J. Lesser, MD | Wake Forest University Health Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CCOP - Western Regional, Arizona | Phoenix | Arizona | 85006-2726 | United States | ||
| CCOP - Santa Rosa Memorial Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29731611 | Background | Vitolins MZ, Case LD, Rapp SR, Lively MO, Shaw EG, Naughton MJ, Giguere J, Lesser GJ. Self-reported adherence and biomarker levels of CoQ10 and alpha-tocopherol. Patient Prefer Adherence. 2018 Apr 24;12:637-646. doi: 10.2147/PPA.S158682. eCollection 2018. | |
| 22682875 | Result | Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG; Wake Forest University Community Clinical Oncology Program Research Base. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013 Mar;11(1):31-42. doi: 10.1016/j.suponc.2012.03.003. |
Not provided
Not provided
There was no run-in period. Everyone enrolled was randomized.
Recruitment occurred in medical clinics
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Arm 1 - CoQ10 + Vitamin E | CoQ10 + Vitamin E 100mg/day in 3 doses |
| FG001 | Arm 2 - Placebo + Vitamin E | Placebo + Vitamin E 100mg/day in 3 doses |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo & Vitamin E |
| Dietary Supplement |
|
| Effects of Coenzyme Q10 on Depression (as Measured by CES-D Short-form) 24 Weeks Following Randomization | CES-D is the Center for Epidemiologic Studies Depression Form. It consists of 20 questions. The total score ranges from 0 to 60. Higher scores indicate greater depression. | 24 weeks |
| Santa Rosa |
| California |
| 95403 |
| United States |
| CCOP - Christiana Care Health Services | Newark | Delaware | 19713 | United States |
| Helen F. Graham Cancer Center at Christiana Hospital | Newark | Delaware | 19713 | United States |
| MBCCOP - Howard University Cancer Center | Washington D.C. | District of Columbia | 20060 | United States |
| CCOP - Mount Sinai Medical Center | Miami Beach | Florida | 33140 | United States |
| MBCCOP - JHS Hospital of Cook County | Chicago | Illinois | 60612 | United States |
| CCOP - Central Illinois | Decatur | Illinois | 62526 | United States |
| CCOP - Northern Indiana CR Consortium | South Bend | Indiana | 46601 | United States |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403 | United States |
| MBCCOP - LSU Health Sciences Center | New Orleans | Louisiana | 70112 | United States |
| CCOP - Michigan Cancer Research Consortium | Ann Arbor | Michigan | 48106 | United States |
| CCOP - Beaumont | Royal Oak | Michigan | 48073-6769 | United States |
| CCOP - Metro-Minnesota | Saint Louis Park | Minnesota | 55416 | United States |
| CCOP - Cancer Research for the Ozarks | Springfield | Missouri | 65804 | United States |
| CCOP - Heartland Research Consortium | St Louis | Missouri | 63131 | United States |
| Missouri Baptist Cancer Center | St Louis | Missouri | 63131 | United States |
| CCOP - St. Louis-Cape Girardeau | St Louis | Missouri | 63141 | United States |
| Alamance Cancer Center at Alamance Regional Medical Center | Burlington | North Carolina | 27216 | United States |
| Southeastern Medical Oncology Center - Goldsboro | Goldsboro | North Carolina | 27534 | United States |
| Pardee Memorial Hospital | Hendersonville | North Carolina | 28791 | United States |
| High Point Regional Hospital | High Point | North Carolina | 27261 | United States |
| Caldwell Memorial Hospital | Lenoir | North Carolina | 28645 | United States |
| CCOP - Southeast Cancer Control Consortium | Winston-Salem | North Carolina | 27104-4241 | United States |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1030 | United States |
| CCOP - Columbus | Columbus | Ohio | 43215 | United States |
| Cancer Centers of the Carolinas - Eastside | Greenville | South Carolina | 29615 | United States |
| South Carolina Cancer Specialists, PA at Hilton Head Medical Center | Hilton Head Island | South Carolina | 29925 | United States |
| CCOP - Upstate Carolina | Spartanburg | South Carolina | 29303 | United States |
| Danville Regional Medical Center | Danville | Virginia | 24541 | United States |
| Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County | Martinsville | Virginia | 24115-4788 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
All participants
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Arm 1 - CoQ10 & Vitamin E | CoQ10 plus Vitamin E 100mg/day in 3 doses |
| BG001 | Arm 2 - Placebo & Vitamin E | Placebo plus Vitamin E 100mg/day in 3 doses |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization | POMS-F is the Profile of Mood States - fatigue scale. It ranges from 0 to 28; higher values indicate greater fatigue. | Posted | Least Squares Mean | Standard Error | units on a scale | 24 weeks |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Effects of Coenzyme Q10 on Quality of Life (as Measured by FACT-B) 24 Weeks Following Randomization | FACT-B stands for Functional Assessment of Cancer Therapy - Breast. It measures quality of life. It is the total of the FACT subscales (emotional, social, functional, and physical) and the Breast subscale. Scores range from 0 to 144; higher scores reflect better overall quality of life. | Posted | Least Squares Mean | Standard Error | units on a scale | 24 weeks |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Effects of Coenzyme Q10 on Depression (as Measured by CES-D Short-form) 24 Weeks Following Randomization | CES-D is the Center for Epidemiologic Studies Depression Form. It consists of 20 questions. The total score ranges from 0 to 60. Higher scores indicate greater depression. | Posted | Least Squares Mean | Standard Error | units on a scale | 24 weeks |
|
|
28 weeks
One month past the end of treatment
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Arm 1 - CoQ10 & Vitamin E | CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day. | 22 | 100 | 89 | 100 | ||
| EG001 | Arm 2 - Placebo & Vitamin E | Placebo-Vitamin E 100 mg/day in 3 doses | 15 | 93 | 84 | 93 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANC | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| WBC | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| allergic reaction | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| anemia | Blood and lymphatic system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| bronchitis | Respiratory, thoracic and mediastinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| cellulitis | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| constipation | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| dehydration | Metabolism and nutrition disorders | CTCAE (3.0) | Systematic Assessment |
| |
| diarrhea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| dizziness | Nervous system disorders | CTCAE (3.0) | Systematic Assessment |
| |
| fatigue | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| fever | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| hypotension | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| ileus | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| infection | Infections and infestations | CTCAE (3.0) | Systematic Assessment |
| |
| pain | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| vomiting | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| L vent sy d | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| abd pain | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| chest pain | Cardiac disorders | CTCAE (3.0) | Systematic Assessment |
| |
| hot flashes | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| nausea | Gastrointestinal disorders | CTCAE (3.0) | Systematic Assessment |
| |
| rash | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Systematic Assessment |
| |
| headache | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| insomnia | General disorders | CTCAE (3.0) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| alopecia | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| anorexia | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| arthralgia | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| constipation | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| cough | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| diarrhea | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| dizziness | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| edema | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| fatigue | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| fever | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| headache | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| heartburn | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| hot flashes | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| infection | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| insomnia | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| irritability | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| mucositis | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| myalgia | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| nausea | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| neuropathy | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| pain | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| rash | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| tachycardia | General disorders | CTCAE (3.0) | Systematic Assessment |
| |
| vomiting | General disorders | CTCAE (3.0) | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Glenn Lesser | Wake Forest University Comprehensive Cancer Center | (336) 713-5440 | glesser@wakehealth.edu |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D005221 | Fatigue |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C024989 | coenzyme Q10 |
| D014810 | Vitamin E |
| ID | Term |
|---|---|
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| >=65 years |
|
| Male |
|
| African-American |
|
| Caucasian |
|
|
|
|
|